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Neuropeptide FF (NPFF) is an octapeptide belonging to the RFamide family of peptides
that have been implicated in a wide variety of physiological functions in the brain including
central cardiovascular and neuroendocrine regulation. The effects of these peptides are
mediated via NPFF1 and NPFF2 receptors that are abundantly expressed in the rat and
human brain. Herein, we review evidence for the role of NPFF in central regulation of
blood pressure particularly within the brainstem and the hypothalamic paraventricular
nucleus (PVN). At a cellular level, NPFF demonstrates distinct responses in magnocellular
and parvocellular neurons of the PVN, which regulate the secretion of neurohypophyseal
hormones and sympathetic outﬂow, respectively. Finally, the presence of NPFF system in
the human brain and its alterations within the hypertensive brain are discussed.
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INTRODUCTION
An understanding of the mechanisms that regulate arterial blood
pressure under physiological conditions and in the context of
pathophysiological situations such as hypertension represents a
major challenge. Essential hypertension is the most common form
of hypertension in humans, although its cause is poorly under-
stood. However, there is substantial evidence to indicate that
essential hypertension may be related to elevated levels of sympa-
thetic nervous activity, which originate within the central nervous
system (CNS).Within theCNS,neural networks governing arterial
blood pressure are contained within topographically segregated
but interactive cell groups represented at all levels of the neu-
raxis. Amongst the many neurotransmitters and neuropeptides
present in these autonomic regions, emerging evidence indicates
that a group of RFamide peptides play an important role in CNS
regulation of cardiovascular function.
WHAT ARE RFamide PEPTIDES?
Historically, the cardioexcitatory peptide FMRFamide from the
bivalve mollusc Macrocallista nimbosa was the ﬁrst peptide iso-
lated and identiﬁedwith anArg-Phe-amideC-terminus (Price and
Greenberg, 1977). Since then many bioactive peptides have been
isolated from invertebrates and vertebrates, and the extended fam-
ily of peptides terminating in a penultimate Arg and an amidated
Phe residue at the C-terminus (RFamide) exists in all phyla (Yang
et al., 1985). These peptides are designated as FMRFamide related
peptides (FaRPs) and collectively referred to as RFamide peptides.
RFamide peptides have been identiﬁed to have diverse biological
functions that include pain modulation, inhibition of food intake,
regulation of water balance, and potent cardiovascular actions
that are mediated through the peripheral and CNSs (Raffa, 1988;
Murase et al., 1996; Panula et al., 1996; Hinuma et al., 2000; Zajac
and Gouarderes, 2000; Sunter et al., 2001; Fukusumi et al., 2003;
Samson et al., 2003; Dockray, 2004).
The recent rapid accumulation of cDNA and genomic DNA
sequence data and the development of bioinformatics have had
a profound impact on the ﬁeld of RFamide peptide research,
especially on gene identiﬁcation and analyses of RFamide pep-
tides and their receptors. While some confusion exists on the
precise nomenclature used in the literature, ﬁve genes encoding
ﬁve prepropeptide precursors that yield ﬁve groups of RFamide
peptides have been described in mammals (Figure 1). These
include the prolactin-releasing peptide (PrRP) family (Hinuma
et al., 1998), the family of neuropeptide FF (NPFF; and related
peptides neuropeptide AF (NPAF), neuropeptide SF (NPSF), and
neuropeptide VF (NPVF); Perry et al., 1997; Vilim et al., 1999;
Bonini et al., 2000; Liu et al., 2001), human RFamide related
peptides (hRFRPs; Hinuma et al., 2000; Fukusumi et al., 2001),
metastin/kisspeptins (Ohtaki et al., 2001), and pyroglutamylated
RFamide peptide (QRFP) (26RFa) family (Chartrel et al., 2003;
Fukusumi et al., 2003). Of these, NPFF peptides and PrRP have
been identiﬁed by our laboratory and others to play an important
role in CNS regulation of cardiovascular function (Thiemermann
et al., 1991; Allard et al., 1995; Jhamandas et al., 1998; Samson
et al., 2000; Jhamandas and MacTavish, 2002). hRFRPs, which
are encoded by a human gene, have a signiﬁcant homology
to the NPFF family of peptides and their receptors (Fukusumi
et al., 2006). Members of the RFRP family (RFRP-1 and RFRP-
3) have been recently identiﬁed as mammalian orthologs of the
avian gonadotropin inhibitory hormone and administration of
the selective NPFF receptor antagonist results in potent secretion
of gonadotropins that is presumed to be mediated via the NPFF1
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FIGURE 1 | Members of the mammalian RFamide family.These include
the prolactin releasing peptide (PrRP) family, the family of NPFF (and related
peptides NPAF, NPSF, and NPVF), human RFamide related peptides (hRFRPs),
metastin/kisspeptins, and QRFP family. Speciﬁc receptors for each family of
peptides have been identiﬁed, although in a number of instances cross-talk
amongst these peptides and their receptors exists (denoted by arrows).
receptor (Pineda et al., 2010), Metastatin/kisspeptins have been
shown to have anti-migratory effects in vitro,metastasis-inhibiting
effects in vivo (Muir et al., 2001; Ohtaki et al., 2001), and identiﬁed
to play an important role in regulation of puberty and reproduc-
tion via gonadotropin release (Richard et al., 2009). QRFPs are
the most recently discovered members of the RFamide family and
postulated to play a role in food intake and increased locomo-
tor activity (Chartrel et al., 2003; Fukusumi et al., 2006; Bruzzone
et al., 2007).
NEUROPEPTIDE FF
CHARACTERISTICS AND TISSUE DISTRIBUTION
Neuropeptide FF (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2) is
an important member of the RFamide peptide family that is
present in the CNS and in the periphery of several mammalian
species including humans (for review see Panula et al., 1996). Ini-
tial interest in NPFF stemmed from its ability to modulate the
antinociceptive effects of opioids (Yang et al., 1985; Chen et al.,
2006; Mouledous et al., 2010), however, emerging studies have
shown that the neuropeptide may play an equally important role
in the central processing of visceral autonomic signals related to
feeding, generation of central cardiovascular responses, stress,
and neuroendocrine regulation (Panula et al., 1996; Jhamandas
and MacTavish, 2003; Simonin et al., 2006). NPFF was the ﬁrst
RFamide peptide to be identiﬁed in mammals (Yang et al., 1985).
The gene for NPFF has been cloned from human, bovine, rat, and
mouse tissue and is highly conserved amongst these species (Yang
et al., 1985; Vilim et al., 1999; Hinuma et al., 2000). The precur-
sor mRNA encodes for NPFF and other related peptides (NPAF,
NPSF, and NPVF) and distribution of the NPFF mRNA in the
brain matches that of NPFF immunoreactivity (Kivipelto et al.,
1989; Vilim et al., 1999; Liu et al., 2001). Immunocytochemical
and receptor autoradiographic studies reveal that brain regions
involved in pain transmission, autonomic and endocrine regula-
tion are enriched in NPFF and its binding sites (Kivipelto et al.,
1989; Allard et al., 1992). Concentrations of NPFF and its recep-
tors in the hypothalamus are amongst the highest in the brain
(Bonini et al., 2000; Zajac and Gouarderes, 2000; Liu et al., 2001).
LIGANDS AND RECEPTORS
Two NPFF receptors, NPFF1 (also referred to as OT7TO22) and
NPFF2 (also known as HLWAR77), have been cloned and char-
acterized (Bonini et al., 2000; Elshourbagy et al., 2000; Zajac and
Gouarderes, 2000). Both receptors are Gi/o protein-coupled when
expressed in Chinese hamster ovary cells or human embryonic
kidney 293 cells (Kotani et al., 2001). These receptors demonstrate
some of the highest levels of expression within the rat and human
brain and spinal cord but data on distribution of speciﬁc NPFF
receptor subtypes in these regions is controversial (Bonini et al.,
2000; Zajac and Gouarderes, 2000). The emerging picture, based
on autoradiographic binding, immunohistochemical and in situ
hybridization studies, is that NPFF1 receptors are predominantly
localized in the hypothalamus and the forebrain, whereas NPFF2
receptors are mainly within the spinal cord, the brainstem visceral
autonomic sensory nuclei, and the hypothalamus (Bonini et al.,
2000; Gouarderes et al., 2002; Zeng et al., 2003; Goncharuk and
Jhamandas, 2004).
NPFF1 receptor has a high afﬁnity for the avian peptide LPLR-
Famide and is the candidate receptor for NPVF, NPSF as well as
hRPRF1 and hRPRF2 peptides (Bonini et al., 2000; Elshourbagy
et al., 2000; Liu et al., 2001). NPFF2, on theother hand, bindsNPFF
and NPAF (Liu et al., 2001; Fukusumi et al., 2006). Interestingly,
PrRP, for which GPR10 has been identiﬁed as the endoge-
nous receptor (Figure 1), has a relatively high afﬁnity for the
NPFF2 receptor and may even have a higher efﬁcacy at the NPFF2
receptor than NPFF (Engström et al., 2003). When administered
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intracerebroventricular (icv), PrRP has been observed to produce
elevations in arterial blood pressure and heart rate that are strik-
ingly similar to those evokedby icvNPFF and in fact canbeblocked
with the selective NPFF antagonist, RF9 (Ma et al., 2009). Thus,
many of the postulated physiological functions of the newer mem-
bers of the RFamide family, PrRP and hRFRPs, may in fact be
mediated via NPFF1 and NPFF2 receptors.
In the past few years, with the synthesis of peptide analogs of
NPFF and related peptides, the essential requirements for ligand
recognition at the NPFF receptor have emerged (Vyas et al., 2006).
However, a major impediment to delineating a physiological role
for NPFF peptides has been a lack of suitable antagonists that show
selectivity for each of the receptors. DesaminoYLFQPQRa was the
ﬁrst analog to attenuate morphine abstinence signs induced by
NPFF (Malin et al., 1995; Prokai et al., 2001) but suffers from poor
bioavailability and/or low afﬁnity for NPFF receptors (Fang et al.,
2005). PFR(Tic)amide has been shown to demonstrate antagonist
activity toward NPFF effect in vitro, but behaves as an agonist
in vivo (Chen et al., 2006). Neuropeptide Y (NPY) ligands such
as BIBP 3226 have been reported to interact with NPFF receptors,
likely on the basis of structural similarities between these receptors
and the C-terminal end of NPY peptides (Mollereau et al., 2002;
Fang et al., 2006). Unfortunately, BIBP 3226 and its derivatives
that were most potent at the NPFF1 receptor were also able to
displace NPYY1 binding (Fang et al., 2005). The discovery of RF9,
a selective antagonist at the NPFF receptor (Simonin et al., 2006)
has represented a signiﬁcant advance in dissecting the role of NPFF
in a variety of physiological functions. This compound potently
and selectively binds to NPFF receptors and indeed blocks the
acute cardiovascular effects induced by icv NPFF. In addition, its
chronic administration blocks delayed and long-lasting opioid-
induced hyperalgesia.
NPFF AND CENTRAL CARDIOVASCULAR AND
NEUROENDOCRINE REGULATION
Experimental evidence supporting a key role for NPFF in cardio-
vascular regulation ﬁrst became apparent in the mid-1980s when
Roth et al. (1987) reported that two NPFF analogs could produce
signiﬁcant pressor effects when administered systemically. Sub-
sequently, focal injections of NPFF into the brainstem nucleus
of tractus solitarius, which is the ﬁrst terminus for cardiovascu-
lar inputs originating from the periphery, resulted in an increase
in blood pressure and bradycardia that could be attenuated with
adrenergic antagonists (Laguzzi et al., 1996). NPFF-synthesizing
neurons in the same brainstem nucleus were shown to be acti-
vated in response to hemorrhage and to a lesser extent acute
drug-induced hypertension (Jhamandas et al., 1998). These NPFF
neurons in turn project to more rostral brainstem and hypothala-
mic cardiovascular centers. Intrathecal and icv administration of
NPFF has been demonstrated to evoke dose-dependent elevations
in arterial blood pressure and heart rate (Jhamandas and Mac-
Tavish, 2002, 2003; Fang et al., 2010). Identity of neural circuits
that participate in centrally generated NPFF responses have been
best studied in the hypothalamus, where icv NPFF evokes activa-
tion of speciﬁc sets of chemically deﬁned paraventricular nucleus
(PVN) neurons, that control CNS humoral and autonomic
outﬂow to the periphery (Jhamandas and MacTavish, 2003).
WHOLE ANIMAL OBSERVATIONS
The PVN is viewed as a key site for homeostasis and a model
nucleus for understanding the central regulation of autonomic
and neuroendocrine function in the brain (Cunningham and
Sawchenko, 1991). The magnocellular neurosecretory cells of the
PVN synthesize either vasopressin or oxytocin and following stim-
ulation, release these hormones from their axonal projections to
the posterior pituitary into the systemic circulation (Sawchenko
and Swanson, 1982). On the other hand, the parvocellular com-
ponent of the PVN is more complex and consists of two broad
categories of cells, neurosecretory cells and non-neurosecretory
(autonomic) cells. The neurosecretory parvocellular neurons are
locatedwithin thedorsalmedial andperiventricular PVNand their
axons terminate on median eminence portal capillaries to facili-
tate the release of “factors” regulating anterior pituitary secretion.
Neurons of this type for example express corticotrophin-releasing
hormone or thyrotrophin-releasing hormone. Parvocellular non-
neurosecretory (autonomic) neurons are located within the dorsal
cap and ventral medial PVN and project their axons to the brain-
stem and the spinal cord. Some of the chemical messengers
expressed in these types of cells include tyrosine hydroxylase, oxy-
tocin, and somatostatin (Roland and Sawchenko, 1993; Dawson
et al., 1998). Central administration of NPFF results in a pref-
erential activation of oxytocin-synthesizing parvocellular PVN
neurons that project to the brainstem. Oxytocinergic projec-
tions to the solitary-vagal complex have previously been shown
to modulate baroreﬂex control of heart rate and other aspects
of circulatory control (Higa et al., 2002; Vela et al., 2010). On
the other hand, icv NPFF does not activate the magnocellular
vasopressin-secreting PVN neurons as measured by Fos immuno-
histochemistry suggesting that the effects of NPFF on these subset
of PVN neurons are inhibitory (Jhamandas et al., 2006). The latter
posit being supported by observation from electrophysiological
studies where NPFF inhibits activity of magnocellular vasopressin
neurons (see below).
CELLULAR ACTIONS OF NPFF
Work from whole animal experiments described above suggests
that the differential activation of subsets of hypothalamic PVN
neurons may result from distinct effects of NPFF on synaptic
activation of magno- and parvocellular neurons of this nucleus.
Indeed, cellular electrophysiological recordings from hypotha-
lamic brain slices reveal that NPFF increases the inhibitory
synaptic drive to magnocellular PVN neurons through a GABA-
synthesizing network of interneurons located within the sub-
PVN region (Roland and Sawchenko, 1993; Jhamandas et al.,
2006; Figure 2). This observation of NPFF augmenting an
inhibition of magnocellular vasopressin-secreting PVN cells ﬁts
well with the in vivo hormone release data, which shows that
hypovolemia-induced vasopressin release from the pituitary is
blunted by centrally administered NPFF (Arima et al., 1996). On
the other hand, NPFF presynaptically disinhibits the GABAer-
gic input to the parvocellular PVN, thereby increasing the net
excitability of these neurons (Figure 2). NPFF also exerts a
distinct depolarizing [tetrodotoxin (TTX)-independent] postsy-
naptic effect on parvocellular PVN neurons (Jhamandas et al.,
2007). NPFF-induced excitation of parvocellular PVN neurons
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FIGURE 2 | Schematic depicting parvocellular and magnocellular
components of the hypothalamic paraventricular nucleus (PVN) and
their projection sites. NPFF differentially modulates GABAergic input
(originating from the adjacent subPVN region) to parvocellular and
magnocellular neurons of the PVN. NPFF inhibits activity of GABAergic
terminals that project to the parvocellular PVN neurons resulting in a
disinhibition of these neurons. On the other hand, NPFF augments GABA
synaptic input to magnocellular PVN neurons.
would be expected to result in an increase in autonomic outﬂow
and sympathetic activation which is precisely what is observed
with acute infusions of icv NPFF in the conscious animal. At
present the lack of selective antagonists acting at NPFF1 versus
NPFF2 receptors makes it difﬁcult to determine whether the dif-
ferential effects of NPFF are in fact mediated via distinct NPFF
receptor subtypes. However, PrRP, which binds to NPFF2 recep-
tors, shows a similar proﬁle of electrophysiological effects on
parvocellular PVN neurons as NPFF. Moreover RF9, a selec-
tive NPFF receptor antagonist, blocks PrRP actions on these
neurons suggesting that both the PrRP and the NPFF effects
in the parvocellular PVN are likely NPFF2 receptor mediated (Ma
et al., 2009).
NPFF AND HUMAN HYPERTENSION
There is currently a paucity of knowledge on the role of NPFF,
and RFamide peptides in general, in human pathophysiolog-
ical states such as essential hypertension. All of our current
knowledge on the role of NPFF in the regulation of arterial
blood pressure is derived from paradigms that rely on study-
ing acute effects of this peptide in experimental animal models,
which do not recapitulate the chronic human hypertensive con-
dition. Nonetheless, anatomical relationships between NPFF and
its receptors within autonomic centers in the human brain may
provide important clues as to the role of this peptide in diverse
biological functions. In this regard, immunohistochemical data
from our laboratory over several years has identiﬁed striking
similarities in the distribution of NPFF and its receptors, NPFF1
and NPFF2, in the normal human brain compared to the rat, a
species in which much of the behavioral and physiological studies
have been done to date(Goncharuk and Jhamandas, 2004, 2008;
Goncharuk et al., 2006). In these studies, we have identiﬁed sig-
niﬁcant numbers of NPFF ﬁbers, NPFF1, and NPFF2 receptors
in the human parvocellular PVN. The relative preponderance
of NPFF (and its receptors) and its intimate anatomical rela-
tionship to important cardiovascular regulatory peptides such as
corticotropin releasing hormone (CRH) in human hypothalamus
suggests an important role for this peptide in hypertension. Inter-
estingly, an up-regulation of CRH-secreting cells in the human
hypothalamic PVN of patients who suffered from essential hyper-
tension has been reported (Goncharuk et al., 2001, 2002). Recent
immunohistochemical observations from post-mortem brain tis-
sue of hypertensive individuals and age-matched controls indicate
a marked reduction of NPFF in discrete cardiovascular brain-
stem and hypothalamic nuclei of hypertensives (Goncharuk et al.,
2011, 2012). In these studies, NPFF immunoreactivity was severely
reduced in a subnuclear zone adjacent to the hypothalamic PVN
and supraoptic nucleus, a site where dense networks of GABAergic
neurons reside. These GABAergic neurons have been identiﬁed to
mediate arterial baroreceptor inputs that control the release of the
pressor hormone vasopressin from the neurohypophysis (Jhaman-
das et al., 1989). Thus loss of NPFF input to GABaergic cells has
the potential to dysregulate cardiovascular reﬂexes and control of
arterial blood pressure.
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CONCLUSION
Emerging evidence indicates that structure of RFamide peptides
including NPFF is remarkably conserved during evolution. What
makes these peptides attractive as therapeutic targets is that they
are involved in essential functions such as pain, appetite and feed-
ing, stress, and cardiovascular regulation. Anatomical, molecular,
and physiological studies indicate that NPFF plays an important
role in brain control of neurohormones and sympathetic outﬂow.
Advances in identiﬁcation and pharmacology of NPFF receptors
and the availability of new and speciﬁc antagonists such as RF9
provide a unique opportunity to identify the speciﬁc role and
relevance of these receptors in physiological function and inpatho-
physiological states such as hypertension. NPFF receptor based
compounds could serve as potential therapeutic agents in the
treatment of hypertension and other autonomic disorders.
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